Related introduction of Arynta (Lisdexamfetamine): What kind of medicine is it used to treat?

Arynta (Lisdexamfetamine) is a central nervous system (CNS) medication approved to treat attention deficit hyperactivity disorder (ADHD) and binge eating disorder (BED). Its first approved oral solution formulation provides a new treatment option for patients who have difficulty swallowing solid dosage forms or who prefer liquid dosage forms. Aryta is indicated for adults and children over 6 years of age with ADHD, as well as adults with moderate to severe bulimia.

Ledexamethasone dimesylate, which was first approved in 2007 under the brand name Vyvanse, is available in two dosage forms: oral capsules and oral chewable tablets. The launch of Aryta has further enriched treatment options, allowing more patients to obtain dosage forms that suit them.

Aryta is taken orally once daily in the morning. Be aware of the risks of abuse, misuse and addiction when using this drug, so follow your doctor's advice when using it. In addition, Aryta also carries a black box warning to remind patients of the risks of serious heart disease, elevated blood pressure and heart rate, and adverse mental reactions. Be alert to the risk of serotonin syndrome, especially when used concomitantly with serotonergic drugs. In addition, long-term use in pediatric patients may affect growth, and peripheral vascular disease (such as Raynaud's phenomenon) also requires attention.

In terms of adverse reactions,Common adverse reactions of Aryta include anorexia, anxiety, decreased appetite, weight loss, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain and vomiting in children aged 6 to 17 years and adults with ADHD. The incidence rates are ≥5%, and are at least twice as high as placebo. Among adults with bulimia, common reactions include dry mouth, insomnia, decreased appetite, increased heart rate, constipation, nervousness and anxiety.

Reference materials:https://www.drugs.com/arynta.html